The 4th HIV Research for Prevention (HIVR4P 2020) biennial global scientific conference will take place in Cape Town, South Africa, on 11-15 October 2020. The conference is among the top three conferences in HIV prevention and focuses exclusively on the growing field of HIV prevention research and its challenges. Participants include basic researchers, clinical scientists and public health specialists, along with social scientists, advocates and funders. Community involvement and participation is also a critical part of the programme.
While HIV prevention science and implementation has made tremendous progress in the areas of PrEP, treatment as prevention and other biomedical interventions, a safe and globally effective HIV vaccine remains elusive. Despite the disappointing early termination of the HVTN 702 efficacy study, a vaccine remains an essential part of HIV prevention – the final “nail in the coffin” for the HIV epidemic, according to Dr Anthony Fauci, Director of NIH’s NIAID
In a fast-changing prevention and treatment landscape and with the results of proof of concept and other late-stage clinical trials on the horizon, it is important, now more than ever, for HIV vaccine R&D to be well represented at HIVR4P 2020.
The conference will also provide 300 full or partial scholarships to representatives and early-career investigators from low- and middle-income countries (LMICs).
The Global HIV Vaccine Enterprise encourages HIV vaccine researches to submit abstracts online from 3 February to 23 April through the HIVR4P website. Late breaker abstracts will be accepted from 23 July – 5 August. Abstracts about HIV vaccine research and development can be submitted across a range of categories from basic science to product implementation.
This is a unique opportunity to disseminate latest findings, better understand the pipeline and timeline for possible success, and outline research and funding gaps to advocate for increased critical resources.
We look forward to seeing you in Cape Town in October!
Established in 2003, the Global HIV Vaccine Enterprise (the Enterprise) became a programme of IAS – the International AIDS Society – in 2018. The Enterprise unites stakeholders to share knowledge, foster collaboration, enable solutions and expand support critical to the development of – and future access to – an HIV vaccine.
Global HIV Vaccine Enterprise
IAS – the International AIDS Society
Avenue de France 23